COMMUNIQUÉS West-GlobeNewswire

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
27/01/2026
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ability to modify [...]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
27/01/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p- [...]
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
27/01/2026
ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
27/01/2026
WESTBROOK, Maine, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced a major expansion of its FOCUSfactor ® [...]
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
27/01/2026
Lisata regains full development rights to certepetide in the Greater China Region BASKING RIDGE, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical- [...]
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
27/01/2026
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, today announced the appointment of Kelly Johnston McKee as Vice President, Strategy & [...]
ABLi Therapeutics Completes Collaboration Agreement with The Michael J. Fox Foundation to include Risvodetinib in Path to Prevention Platform Trial
27/01/2026
Study aims to evaluate promising therapeutics that could slow or halt progression of Parkinson’s disease in prodromal patients ATLANTA and BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a [...]
SRx Health Solutions Allocates Further Capital to its Digital Asset Treasury Hedging Strategy, Bringing Total Allocation to $18 Million
27/01/2026
NORTH PALM BEACH, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced allocating further capital to its digital treasury management strategy with the [...]
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
27/01/2026
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia [...]
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
27/01/2026
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage [...]
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
27/01/2026
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS- [...]
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
27/01/2026
SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces that [...]
Sevaro Health Expands Leadership Team with Key Appointments
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Sevaro Health , the company transforming neurological and specialty care through advanced technology, today announced the appointments of Carl Dugart as Chief Technology [...]
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
Verano Continues Expansion of Florida Operations with the Opening of MÜV Deltona, Elevating the Company’s Retail Footprint to 83 Florida Locations and 160 Dispensaries Nationwide
27/01/2026
MÜV Deltona is located at 1670 Providence Boulevard, a busy thoroughfare with an average daily traffic count of 8,600 vehicles 1 The new Deltona dispensary complements four existing MÜV locations in Volusia County, a [...]
Evestia Clinical Acquires ICRC-Weyer to Enhance Global Full-Service Clinical Research Capabilities
27/01/2026
Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe LONDON, Jan. 27, [...]
SweetWater 420 Fest Unveils Powerhouse 2026 Lineup: Umphrey’s McGee, Thievery Corporation & Chromeo to Headline
27/01/2026
April 17-18: SweetWater’s Biggest Music Festival Returns—Tickets on Sale Now ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in [...]
StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers
27/01/2026
PRESS RELEASE StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers The collaboration will inform patient selection for treatment with STX-1, a [...]

Pages